Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026Expects to expand seasonal vaccine…
Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026Expects to expand seasonal vaccine…
~35% of erectile dysfunction patients in a $3.2 billion market are non-responders to brands including Viagra and Cialis, and these…
Vaso Corporation137 Commercial StreetPlainview, New York 11803Tel: (516) 997-4600 Fax: (516) 997-2299 Investor Contact:Jonathan NewtonInvestor RelationsPhone: 516-997-4600 Email: jnewton@vasocorporation.com PLAINVIEW,…
PETACH TIKVA, Israel, Nov. 19, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative…
ProPhase Labs in discussions for strategic initiative to realize significant underlying value in the Company. Voting for Current Proxy Critically…
RESEARCH TRIANGLE PARK, N.C., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a…
Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free…
Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), a leader in regenerative…
Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), a leader in regenerative…